Lexeo Therapeutics said it plans a pivotal gene therapy trial in PKP2 arrhythmogenic cardiomyopathy with an eye on accelerated approval after interim Phase I/II HEROIC-PKP2 data. The company reported that in the high-dose group, non-sustained ventricular tachycardia frequency fell by a mean of 80% from baseline to each patient’s latest assessment. Lexeo also reported a mean 44% reduction in premature ventricular contractions. The company said the FDA is open to using NSVT episode frequency as the primary endpoint in the pivotal study to support a faster regulatory path. If validated, the approach could become a template for endpoint selection in gene therapy where clinical event counts can be hard to shift on shorter timelines.